Rotavirus vaccines for infants in developing countries in Africa and Asia: Considerations from a world health organization-sponsored consultation

Journal of Infectious Diseases

Volumn 200, Issue SUPPL. 1, 2009, Pages

  Steele, A Duncan ^a,b   Patel, Manish ^c   Parashar, Umesh D ^c   Victor, John C ^b   Aguado, Teresa ^a   Neuzil, Kathleen M ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b PATH   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; MATERNAL ANTIBODY; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE;

ASIA; BANGLADESH; CAUSE OF DEATH; CLINICAL TRIAL; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PROGRAM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG UPTAKE; FACTORIAL ANALYSIS; GASTROENTERITIS; GEOGRAPHIC DISTRIBUTION; GHANA; HUMAN; HUMAN ROTAVIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INDUSTRIALIZATION; INFANT MORTALITY; INTUSSUSCEPTION; KENYA; LICENSING; MALAWI; MALI; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; REVIEW; RURAL AREA; SEROPREVALENCE; SOUTH AFRICA; TREATMENT OUTCOME; URBAN AREA; VIET NAM; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS SHEDDING; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

AFRICA; ASIA; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; REFERRAL AND CONSULTATION; ROTAVIRUS VACCINES; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 72849126427     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605042     Document Type: Review

References (22)

1. Parashar U, Burton A, La nata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200(Suppl 1):S9-15 (in this supplement).
2. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003; 81:197-204.
3. Bresee JS, Hummelman E, Nelson EAS, Glass RI. Rotavirus in Asia: the importance of surveillance for informing decisions about rotavirus vaccines. J Infect Dis 2005; 192(Suppl 1):S1-5.
4. de Zoysa I, Feachem RV. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull World Health Organ 1985; 63:569-583 (Pubitemid 16237127) (Pubitemid 16237127)
5. World Health Organization report of the meeting on rotavirus vaccines for the immunization of children in developing countries. Geneva: World Health Organization, 1997.
6. World Health Organization report of the meeting on the future directions for rotavirus research in developing countries. Geneva: World Health Organization, 2000.
7. Ruiz-Palacios GM, Perez-Schael I, Velasquez R, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.N Engl J Med 2006; 354:11-22.
8. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33. (Pubitemid 43048948) (Pubitemid 43048948)
9. De Oliveira LH, Danovaro-Holliday MC, Ruiz Matus C, Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons. Expert Rev Vaccines 2008; 7:345-353
10. Glass RI, Bresee JS, Turcois R, Fischer TK, Parashar U, Steele AD. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005; 192(Suppl 1):S160-6.
11. World Health Organization conclusions and recommendations from SAGE. Wkly Epidemiol Rec 2006; 81:8.
12. World Health Organization guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral). WHO technical report series no. 941. Geneva: World Health Organization, 2007.
13. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis 2009; 200(Suppl 1):S39-48 (in this supplement).
14. Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009; 200(Suppl 1):S28-38 (in this supplement).
15. World Health Organization (WHO). List of member states by WHO region and mortality stratum, 2003. Available at: http://www.who.int/whr/2003/en/member- tates-82-184-n.pdf. Accessed 23 June 2008.
16. Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009; 27: 1333-1339
17. Steele AD, De Vos BV, Tumbo JM, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2008 (Epub ahead of print).
18. Steele AD, Cunliffe N, Tumbo J, Madhi SA, De Vos B, Bouckenooghe A. A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children. J Infect Dis 2009; 200(Suppl 1):S57-62 (in this supplement).
19. Report of the Global Advisory Committee on Vaccine Safety. Wkly Epidemiol Rec 2006; 81:16-17
20. Centers for Disease Control and Prevention. Postmarketing monitoring of intussusception after RotaTeq vaccination - United States, February 1, 2006-February 15, 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 218-222
21. Ward RD, McNeal MM, Steele AD. Does the world need another rotavirus vaccine? Ther Clin Risk Manag 2008; 4:49-63.
22. World Health Organization position paper on rotavirus vaccines. Wkly Epidemiol Rec 2007; 82:285-296